Orion published Interim Report for January-September 2020 on Wednesday, 21 October 2020. The report, related presentation material and a link to live webcast are available here.
Orion Investor Relations have received several questions related to the coronavirus (COVID-19) pandemia and its impacts on Orion. We have listed here answers to some frequently asked questions.
The 2020 Annual General Meeting of Orion was held on Wednesday, 6 May 2020. The decisions and related material are available here.
Responsibility is one incentive when retail investors seek investments. Pharmaceuticals and healthcare is one of the most interesting sectors.
Research and development are Orion's strengths, and the company will continue to invest in them. The target is to increase net sales 1.5-fold by 2025.
The latest Corporate Governance Statement of Orion Corporation is available at the archive of Corporate Governance Statements.
|10/29/2020||Prosecutor pressed charges against a member of Orion’s Board of Directors for a suspected securities market offence – the suspected offence is not related to Orion|
|10/21/2020||Composition of the Nomination Committee of Orion Corporation|
|10/21/2020||Orion Group Interim Report 1-9/2020|
|10/19/2020||Orion upgrades full-year outlook for 2020|
|11/10/2020||Orion invests EUR 17 million in its production plants in Turku|
|11/4/2020||Orion Research Foundation grants 1 014 400 euros for research in 2021|
|10/19/2020||Orion's statutory co-operation negotiations completed regarding the Research & Development function|
|10/6/2020||Orion publishes Interim Report for January-September 2020 on Wednesday 21 October 2020|
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
Orion Corporation has been included in the globally recognised FTSE4Good Index.